NASDAQ:CMRX Chimerix - CMRX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $1.77 -0.03 (-1.67%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$1.77▼$1.8250-Day Range$1.70▼$2.3552-Week Range$1.27▼$6.43Volume508,487 shsAverage Volume610,053 shsMarket Capitalization$155.83 millionP/E Ratio1.01Dividend YieldN/APrice Target$8.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Chimerix MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside380.2% Upside$8.50 Price TargetShort InterestHealthy3.57% of Float Sold ShortDividend StrengthN/ASustainability-2.49Upright™ Environmental ScoreNews Sentiment0.45Based on 2 Articles This WeekInsider TradingSelling Shares$5,685 Sold Last QuarterProj. Earnings GrowthDecreasingFrom $1.97 to ($0.90) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.37 out of 5 starsMedical Sector257th out of 1,049 stocksPharmaceutical Preparations Industry124th out of 514 stocks 3.5 Analyst's Opinion Consensus RatingChimerix has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.50, Chimerix has a forecasted upside of 380.2% from its current price of $1.77.Amount of Analyst CoverageChimerix has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted3.57% of the float of Chimerix has been sold short.Short Interest Ratio / Days to CoverChimerix has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Chimerix has recently increased by 4.33%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldChimerix does not currently pay a dividend.Dividend GrowthChimerix does not have a long track record of dividend growth. Previous Next 4.1 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreChimerix has received a 58.63% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Pox medications" and "Clinical research services for cancer" products. See details.Environmental SustainabilityThe Environmental Impact score for Chimerix is -2.49. Previous Next 1.9 News and Social Media Coverage News SentimentChimerix has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Chimerix this week, compared to 3 articles on an average week.Search InterestOnly 7 people have searched for CMRX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Chimerix to their MarketBeat watchlist in the last 30 days. This is an increase of 25% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Chimerix insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,685.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Chimerix is held by insiders.Percentage Held by Institutions58.03% of the stock of Chimerix is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Chimerix are expected to decrease in the coming year, from $1.97 to ($0.90) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Chimerix is 1.01, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 129.54.Price to Earnings Ratio vs. SectorThe P/E ratio of Chimerix is 1.01, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 117.73.Price to Book Value per Share RatioChimerix has a P/B Ratio of 2.24. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Chimerix (NASDAQ:CMRX) StockChimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs include ONC201 a program for treating tumors which harbor the H3 K27M mutation in recurrent diffuse midline glioma patients; ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist that demonstrated enhanced non-competitive DRD2 antagonism relative to ONC201, which is in Phase I clinical trials to treat solid tumors; ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for solid tumors and hematological malignancies, including pancreatic cancer and leukemias; and dociparstat sodium (DSTAT), which inhibits the activities of key proteins implicated in the resistance of acute myeloid leukemia blasts and leukemic stem cells to chemotherapy. The company has license agreements with Biomedical Advanced Research and Development Authority for the development of brincidofovir for use in the treatment of smallpox; Cantex Pharmaceuticals, Inc. to develop and commercialize a glycosaminoglycan compound; and SymBio Pharmaceuticals to develop, manufacture, and commercialize BCV for various human indications. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.Read More Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address CMRX Stock News HeadlinesJanuary 5, 2023 | finance.yahoo.comChimerix to Present at 41st Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2023 | thestreet.comWhy Chimerix (CMRX) Stock Is Tanking TodayJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 29, 2022 | finance.yahoo.comChimerix (CMRX) Upgraded to Buy: What Does It Mean for the Stock?November 14, 2022 | bizjournals.comHedge fund urges Durham drugmaker Chimerix to liquidateNovember 10, 2022 | finance.yahoo.comRubric Capital Management Sends Letter to Chimerix Board of DirectorsNovember 10, 2022 | finance.yahoo.comChimerix Responds to Rubric Capital ManagementNovember 4, 2022 | finance.yahoo.comBuy 3 of the Best Stocks by Using Net Income RatioJanuary 30, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 3, 2022 | finance.yahoo.comChimerix (CMRX) Beats Q3 Earnings EstimatesNovember 3, 2022 | finance.yahoo.comChimerix Reports Third Quarter 2022 Financial Results and Provides Operational UpdateOctober 27, 2022 | finance.yahoo.comChimerix to Report Third Quarter 2022 Financial Results and Provide an Operational Update on November 3, 2022October 11, 2022 | nasdaq.comWill UnitedHealth Group (UNH) Beat Q3 Earnings Estimates? - NasdaqOctober 5, 2022 | proactiveinvestors.comKazia Therapeutics takes Phase 2 study of paxalisib international; opens two sites in Australia - Proactive Investors USAOctober 5, 2022 | uk.investing.com$1.2 Million Bet On ChromaDex? Check Out These 4 Penny Stocks Insiders Are Buying By Benzinga - Investing.com UKSeptember 28, 2022 | bizjournals.comDurham pharma nets $238M for smallpox drug with more payouts lined up - The Business JournalsSeptember 27, 2022 | finance.yahoo.comEmergent BioSolutions closes acquisition of smallpox drug from ChimerixSeptember 26, 2022 | globenewswire.comEmergent BioSolutions Completes Acquisition of Exclusive Worldwide Rights to TEMBEXA® (brincidofovir), the First FDA-Approved Smallpox Oral Antiviral for All Ages - GlobeNewswireSeptember 26, 2022 | globenewswire.comChimerix Announces Closing of TEMBEXA Sale to Emergent BioSolutions - GlobeNewswireSeptember 11, 2022 | nasdaq.comWe Think Chimerix (NASDAQ:CMRX) Needs To Drive Business Growth Carefully - NasdaqSeptember 10, 2022 | finance.yahoo.comInstitutional investors own a significant stake of 49% in Chimerix, Inc. (NASDAQ:CMRX)September 6, 2022 | benzinga.comChimerix (CMRX) – Chimerix to Present at H.C. Wainwright 24th Annual Global Investment Conference - BenzingaSeptember 6, 2022 | finance.yahoo.comChimerix to Present at H.C. Wainwright 24th Annual Global Investment ConferenceSeptember 2, 2022 | nasdaq.comImplied Volatility Surging for Chimerix (CMRX) Stock Options - NasdaqSeptember 1, 2022 | finance.yahoo.comImplied Volatility Surging for Chimerix (CMRX) Stock OptionsAugust 31, 2022 | benzinga.com(BVNRY), Chimerix (CMRX) – Testing, Treatment, and Vaccines are the Three Ways Companies Can Fight Monkey - BenzingaAugust 31, 2022 | benzinga.comChimerex, Inc. (CMRX) – Chimerix's Return On Capital Employed Insights - BenzingaSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive CMRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Chimerix and its competitors with MarketBeat's FREE daily newsletter. Email Address CMRX Company Calendar Last Earnings11/03/2022Today1/30/2023Next Earnings (Estimated)3/07/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:CMRX CUSIPN/A CIK1117480 Webwww.chimerix.com Phone(919) 806-1074Fax919-806-1146Employees87Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.50 High Stock Price Forecast$11.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+380.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)$1.75 Trailing P/E Ratio1.01 Forward P/E Ratio0.90 P/E GrowthN/ANet Income$-173,240,000.00 Net Margins464.75% Pretax Margin465.22% Return on Equity147.04% Return on Assets119.67% Debt Debt-to-Equity RatioN/A Current Ratio16.44 Quick Ratio16.44 Sales & Book Value Annual Sales$1.98 million Price / Sales78.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book2.24Miscellaneous Outstanding Shares88,040,000Free Float80,825,000Market Cap$155.83 million OptionableOptionable Beta1.17 Key ExecutivesMr. Michael A. Sherman M.B.A. (Age 57)CEO, Pres & Director Comp: $987.2kMr. Michael T. Andriole M.B.A. (Age 50)Chief Bus. Officer, Sec. & CFO Comp: $616.9kDr. Allen S. Melemed M.B.A. (Age 59)M.D., Chief Medical Officer Comp: $622.17kMr. David Jakeman CPA (Age 45)Exec. Director of Fin. & Accounting and Principal Accounting Officer Dr. Roy W. WareChief Manufacturing & Technology OfficerDr. Randall LanierChief Science OfficerMs. Michelle LaSpalutoVP of Strategic Planning & Investor RelationsDr. Michael A. Alrutz (Age 53)Sr. VP, Gen. Counsel & Corp. Sec. Dr. Joshua E. AllenChief Technology Officer of ImipridonesMore ExecutivesKey CompetitorsXeris BiopharmaNASDAQ:XERSOmerosNASDAQ:OMERInterCureNASDAQ:INCRGlycoMimeticsNASDAQ:GLYCscPharmaceuticalsNASDAQ:SCPHView All CompetitorsInsiders & InstitutionsDavid JakemanSold 3,230 sharesTotal: $5,684.80 ($1.76/share)Strs OhioBought 35,600 shares on 1/26/2023Ownership: 0.092%Allspring Global Investments Holdings LLCBought 18,070 shares on 1/23/2023Ownership: 0.426%Clear Harbor Asset Management LLCSold 14,500 shares on 1/20/2023Ownership: 0.026%Assenagon Asset Management S.A.Sold 23,364 shares on 1/12/2023Ownership: 0.300%View All Insider TransactionsView All Institutional Transactions CMRX Stock - Frequently Asked Questions Should I buy or sell Chimerix stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chimerix in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CMRX shares. View CMRX analyst ratings or view top-rated stocks. What is Chimerix's stock price forecast for 2023? 3 analysts have issued 12-month price targets for Chimerix's stock. Their CMRX share price forecasts range from $6.00 to $11.00. On average, they expect the company's share price to reach $8.50 in the next twelve months. This suggests a possible upside of 378.9% from the stock's current price. View analysts price targets for CMRX or view top-rated stocks among Wall Street analysts. How have CMRX shares performed in 2023? Chimerix's stock was trading at $1.86 at the beginning of 2023. Since then, CMRX shares have decreased by 4.6% and is now trading at $1.7750. View the best growth stocks for 2023 here. When is Chimerix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023. View our CMRX earnings forecast. How were Chimerix's earnings last quarter? Chimerix, Inc. (NASDAQ:CMRX) posted its earnings results on Thursday, November, 3rd. The biopharmaceutical company reported $2.75 earnings per share for the quarter, topping the consensus estimate of $2.10 by $0.65. The biopharmaceutical company earned $32.56 million during the quarter, compared to the consensus estimate of $205.30 million. Chimerix had a trailing twelve-month return on equity of 147.04% and a net margin of 464.75%. What other stocks do shareholders of Chimerix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Chimerix investors own include Melinta Therapeutics (MLNT), Immunomedics (IMMU), Synergy Pharmaceuticals (SGYP), Novavax (NVAX), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), Inovio Pharmaceuticals (INO), OPKO Health (OPK), VBI Vaccines (VBIV) and TherapeuticsMD (TXMD). What is Chimerix's stock symbol? Chimerix trades on the NASDAQ under the ticker symbol "CMRX." Who are Chimerix's major shareholders? Chimerix's stock is owned by a variety of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.43%), Assenagon Asset Management S.A. (0.30%), Strs Ohio (0.09%), Clear Harbor Asset Management LLC (0.03%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Jakeman, Fred A Middleton, Garrett Nichols, Martha J Demski, Michael A Sherman, Michael T Andriole and Robert J Meyer. View institutional ownership trends. How do I buy shares of Chimerix? Shares of CMRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Chimerix's stock price today? One share of CMRX stock can currently be purchased for approximately $1.78. How much money does Chimerix make? Chimerix (NASDAQ:CMRX) has a market capitalization of $156.27 million and generates $1.98 million in revenue each year. The biopharmaceutical company earns $-173,240,000.00 in net income (profit) each year or $1.75 on an earnings per share basis. How can I contact Chimerix? Chimerix's mailing address is 2505 MERIDIAN PARKWAY SUITE 100, DURHAM NC, 27713. The official website for the company is www.chimerix.com. The biopharmaceutical company can be reached via phone at (919) 806-1074, via email at ir@chimerix.com, or via fax at 919-806-1146. This page (NASDAQ:CMRX) was last updated on 1/30/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.